Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot safety and pharmacokinetics study of AERUMAB 11 (KBPA-101) in ventilator associated pneumonia due to serotype O11 Pseudomonas aeruginosa
2007-000442-12Phase 2Completed
- Sponsor
- Kenta Biotech AG
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobacumab in ventilator-associated pneumonia (VAP), sponsored by Kenta Biotech AG. Primary endpoints: Safety and tolerability of AERUMAB 11, Repeated-dose pharmacokinetics of AERUMAB 11 and 1 more. Started Apr 2007; status: completed.
02
Drugs
panobacumab
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2007-000442-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000442-12.